Skip to main content
Premium Trial:

Request an Annual Quote

Psychiatric Genomics to Use High Throughput Genomics Array Kits

NEW YORK, Feb. 5-Psychiatric Genomics will use array kit products from Tucson, Ariz.-based High Throughput Genomics in its search for drugs to treat psychiatric disorders, the companies said on Jan. 31.


As part of the agreement, PsyGenomics will designate genes of interest to be included into the custom-made kits. The kits will be incorporated into PsyGenomics' own drug discovery platform.


Financial details of the arrangement were not revealed.


HTG's ArrayPlate kits, designed for drug discovery and diagnostic development, are 96-well universal array microplates with custom reagent kits. The plates are designed to allow multiple assays per well.


Psychiatric Genomics, based in Gaithersburg, Md., focuses on new treatments for mental illness. Its research includes novel gene discovery, high-throughput cellular screening, and lead candidate optimization.


The privately held company was founded in 2000. Oxford Bioscience Partners is the lead investor.


High Throughput Genomics was established as a subsidiary of Tucson combinatorial chemistry firm Systems Integration Drug Discovery Company in 1997. When that company was sold to San Diego's Discovery Partners International in 2001, HTG was spun off to SIDDCO shareholders. It is also privately held.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.